于明明 - 中国海洋大学

个人简介

教育背景： 2003.09 - 2007.06，中国海洋大学，药学，学士 2007.09 - 2010.07，中国海洋大学，药物化学，硕士 2010.09 - 2011.07，中国海洋大学，药物化学，博士 2011.08 - 2012.12，美国佛罗里达大学，定量药理学，联合培养博士研究生 2013.01 - 2013.08，美国马里兰大学，定量药理学，联合培养博士研究生 2013.09 - 2014.01，中国海洋大学，药物化学，博士工作经历： 2014.03 - 2015.09，上海药物研究所药物代谢中心，博士后 2015.10 - 2017.12，美国马里兰大学药学院，博士后 2017.12 - 至今，中国海洋大学医药学院，副教授

研究领域

临床前药物代谢与药物动力学研究定量药理学（PK/PD 模型研究）新药研发过程中先导药物药代特性筛选和评价

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Zhu S, Zhang J, Lv Z, Zhu P, Oo C, Yu M*, Sy SKB*.2022. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet 61:1427-1441. 2. Zhu S, Song C, Zhang J, Diao S, Heinrichs TM, Martins FS, Lv Z, Zhu Y, Yu M*, Sy SKB*.2022. Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii. Front Microbiol 13:1013939. 3.Zhang Y, Zhang R, Sy SKB, Li Z, Zhu S, Zhou M, Song C, Zhang J, Lv Z, Liu J, Qin L*, Yu M*,2022. Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of Riemerella anatipestifer in Ducks. Microb Drug Resist 28:832-840. 4. Feng K, Jia N, Zhu P, Sy S, Liu Y, Dong D, Zhu S, Zhang J, Liu Y, Martins FS, Gong H, Lv Z, Yu M*, Sy SKB, Zhu Y.2021. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-beta-lactamases. J Antimicrob Chemother 76:2875-2883. 5. Hassan HE, Kelly D, Honick M, Shukla S, Ibrahim A, Gorelick DA, Glassman M, McMahon RP, Wehring HJ, Kearns AM, Feldman S, Yu M, Bauer K, Wang JB*.2017. Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Pharmacol 57:151-160. 6. Yu M, Gao Z, Dai X, Gong H, Zhang L, Chen X, Zhong DF*, Sy SK*. 2017. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. Clin Pharmacokinet 56:65-76. 7.Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF*.2015. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin 36:1528-36. 8. de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR*.2014. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58:6242-50.